ASCO 2026 | ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky, MD, MS, Emory University, Atlanta, GA, progression-free survival after next line of treatment (PFS2) analyses from ASCENT-04 (NCT05382286), evaluating sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in patients with treatment naïve PD-L1-positive metastatic triple-negative breast cancer (mTNBC). Results demonstrated improved PFS2 with sacituzumab govitecan plus pembrolizumab despite crossover, indicating clinically relevant continued benefit beyond first progression and further supporting this combination as a potential new standard of care in this setting. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
